<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38746454</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Oxidative Stress is a shared characteristic of ME/CFS and Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.05.04.592477</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.05.04.592477</ELocationID><Abstract><AbstractText>More than 65 million individuals worldwide are estimated to have Long COVID (LC), a complex multisystemic condition, wherein patients of all ages report fatigue, post-exertional malaise, and other symptoms resembling myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). With no current treatments or reliable diagnostic markers, there is an urgent need to define the molecular underpinnings of these conditions. By studying bioenergetic characteristics of peripheral blood lymphocytes in over 16 healthy controls, 15 ME/CFS, and 15 LC, we find both ME/CFS and LC donors exhibit signs of elevated oxidative stress, relative to healthy controls, especially in the memory subset. Using a combination of flow cytometry, bulk RNA-seq analysis, mass spectrometry, and systems chemistry analysis, we also observed aberrations in ROS clearance pathways including elevated glutathione levels, decreases in mitochondrial superoxide dismutase levels, and glutathione peroxidase 4 mediated lipid oxidative damage. Critically, these changes in redox pathways show striking sex-specific trends. While females diagnosed with ME/CFS exhibit higher total ROS and mitochondrial calcium levels, males with an ME/CFS diagnosis have normal ROS levels, but larger changes in lipid oxidative damage. Further analyses show that higher ROS levels correlates with hyperproliferation of T cells in females, consistent with the known role of elevated ROS levels in the initiation of proliferation. This hyperproliferation of T cells can be attenuated by metformin, suggesting this FDA-approved drug as a possible treatment, as also suggested by a recent clinical study of LC patients. Thus, we report that both ME/CFS and LC are mechanistically related and could be diagnosed with quantitative blood cell measurements. We also suggest that effective, patient tailored drugs might be discovered using standard lymphocyte stimulation assays.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Vishnu</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Wilhelmy</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Ellis J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Basil</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Cervantes</LastName><ForeName>Layla</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mallajosyula</LastName><ForeName>Vamsee A</ForeName><Initials>VA</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Ronald W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Younis</LastName><ForeName>Shady</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4319-1738</Identifier></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>William H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Sadasivan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mischel</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AI153559</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI057229</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>15</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38746454</ArticleId><ArticleId IdType="pmc">PMC11092775</ArticleId><ArticleId IdType="doi">10.1101/2024.05.04.592477</ArticleId><ArticleId IdType="pii">2024.05.04.592477</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>